Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INO 464 (Primary)
Indications Multiple system atrophy
Focus Adverse reactions; First in man
Acronyms HORIZON
Sponsors Biogen; Ionis Pharmaceuticals

Most Recent Events

24 Jan 2024 Planned End Date changed from 1 Dec 2025 to 1 Sep 2027.
24 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Sep 2027.
26 Jul 2022 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com